Skip to main content
SpringerLink
Log in

Selective Progesterone Receptor Modulators for Contraception with Added Health Benefits

  • Chapter
  • First Online:
Menstrual Cycle Related Disorders

Part of the book series: ISGE Series ((ISGE))

Abstract

Selective progesterone receptor modulators (SPRMs), such as mifepristone and ulipristal acetate, are being studied for a variety of uses. They have already proved useful for women’s health in terms of contraception and are continuing to be studied in innovative ways to improve the lives of women through novel and acceptable contraceptive methods with potential added health benefits. These drugs are showing promise in the treatment of leiomyoma, endometriosis, and breast disease. Studies are ongoing on contraception efficacy, new indications, long-term safety, and side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 69.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Family Planning/Contraception World Health Organization 2017. Available from: http://www.who.int/mediacentre/factsheets/fs351/en/. Updated July 2017.

  2. Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet. 2012;380(9837):149–56.

    Article  PubMed  Google Scholar 

  3. Division UNDoEaSAP. World contraceptive patterns 2013. New York 2013, October 2013.

    Google Scholar 

  4. Kopp Kallner H, Thunell L, Brynhildsen J, Lindeberg M, Gemzell Danielsson K. Use of contraception and attitudes towards contraceptive use in Swedish women—a nationwide survey. PLoS One. 2015;10(5):e0125990.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The contraceptive CHOICE project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol. 2010;203(2):115.e1–7.

    Article  Google Scholar 

  6. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293–307.

    Article  CAS  PubMed  Google Scholar 

  7. Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175–89.

    Article  CAS  PubMed  Google Scholar 

  8. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids. 2003;68(10–13):981–93.

    Article  CAS  PubMed  Google Scholar 

  9. Bygdeman M, Swahn ML, Gemzell-Danielsson K, Svalander P. Mode of action of RU 486. Ann Med. 1993;25(1):61–4.

    Article  CAS  PubMed  Google Scholar 

  10. Gupta JK, Johnson N. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Lancet. 1990;335(8700):1238–40.

    Article  CAS  PubMed  Google Scholar 

  11. Ben-Chetrit A, Eldar-Geva T, Lindenberg T, Farhat M, Shimonovitz S, Zacut D, et al. Mifepristone does not induce cervical softening in non-pregnant women. Hum Reprod. 2004;19(10):2372–6.

    Article  CAS  PubMed  Google Scholar 

  12. Baird DT. Mode of action of medical methods of abortion. J Am Med Womens Assoc (1972). 2000;55(3 Suppl):121–6.

    CAS  Google Scholar 

  13. Baev OR, Rumyantseva VP, Tysyachnyu OV, Kozlova OA, Sukhikh GT. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2017;217:144–9.

    Article  CAS  PubMed  Google Scholar 

  14. Bygdeman M, Danielsson KG, Marions L, Swahn ML. Contraceptive use of antiprogestin. Eur J Contracept Reprod Health Care. 1999;4(2):103–7.

    Article  CAS  PubMed  Google Scholar 

  15. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod. 1993;8(6):870–3.

    Article  CAS  PubMed  Google Scholar 

  16. Marions L, Viski S, Danielsson KG, Resch BA, Swahn ML, Bygdeman M, et al. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod. 1999;14(11):2788–90.

    Article  CAS  PubMed  Google Scholar 

  17. Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab. 2002;87(1):63–70.

    Article  CAS  PubMed  Google Scholar 

  18. Pei K, Xiao B, Jing X, Lu S, Wei L, Zhao H. Weekly contraception with mifepristone. Contraception. 2007;75(1):40–4.

    Article  CAS  PubMed  Google Scholar 

  19. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P, Group VAS. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92(9):3582–9.

    Article  CAS  PubMed  Google Scholar 

  20. Heikinheimo O, Vani S, Carpen O, Tapper A, Harkki P, Rutanen EM, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod. 2007;22(9):2515–22.

    Article  CAS  PubMed  Google Scholar 

  21. Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception. 2013;87(3):314–8.

    Article  CAS  PubMed  Google Scholar 

  22. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591–8.

    Article  CAS  PubMed  Google Scholar 

  23. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31(6):556–69.

    Article  CAS  PubMed  Google Scholar 

  24. Berger C, Boggavarapu NR, Menezes J, Lalitkumar PG, Gemzell-Danielsson K. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod. 2015;30(4):800–11.

    Article  CAS  PubMed  Google Scholar 

  25. Boggavarapu NR, Berger C, von Grothusen C, Menezes J, Gemzell-Danielsson K, Lalitkumar PG. Effects of low doses of mifepristone on human embryo implantation process in a three-dimensional human endometrial in vitro co-culture system. Contraception. 2016;94(2):143–51.

    Article  CAS  PubMed  Google Scholar 

  26. Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update. 2004;10(4):341–8.

    Article  CAS  PubMed  Google Scholar 

  27. Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;4:CD010770.

    PubMed  Google Scholar 

  28. Donnez J, Vazquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–73.e1–18.

    Article  CAS  PubMed  Google Scholar 

  29. Seitz C, Bumbuliene Z, Costa AR, Heikinheimo O, Heweker A, Hudecek R, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials. 2017;55:56–62.

    Article  PubMed  Google Scholar 

  30. Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. Hum Reprod. 1995;10(12):3264–71.

    Article  CAS  PubMed  Google Scholar 

  31. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab. 1996;81(5):1933–9.

    CAS  PubMed  Google Scholar 

  32. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65(1):23–8.

    Article  CAS  PubMed  Google Scholar 

  33. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod. 1994;9(Suppl 1):116–20.

    Article  PubMed  Google Scholar 

  34. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol. 1998;178(6):1151–6.

    Article  CAS  PubMed  Google Scholar 

  35. Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, et al. Progesterone receptor modulators for endometriosis. Cochrane Database Syst Rev. 2017;7:CD009881.

    PubMed  Google Scholar 

  36. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008;23(9):2072–9.

    Article  CAS  PubMed  Google Scholar 

  37. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006;314(5804):1467–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of OB/GYN, Department of Women’s and Children’s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    Kristina Gemzell-Danielsson

  2. Department of OB/GYN, University of California, Irvine, Irvine, CA, USA

    Marielle E. Meurice

Authors
  1. Kristina Gemzell-Danielsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marielle E. Meurice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristina Gemzell-Danielsson .

Editor information

Editors and Affiliations

  1. Wake Forest SOM/WF Baptist Medical Center, Executive Director Women’s Health Services, Winston Salem, NC, USA

    Sarah L. Berga

  2. International Society of Gynecological Endocrinology, University of Pisa, Pisa, Italy

    Andrea R. Genazzani

  3. Department of Obstetrics and Gynecology, New York University, New York, NY, USA

    Frederick Naftolin

  4. Department of Obstetrics and Gynaecology, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

    Felice Petraglia

Rights and permissions

Reprints and permissions

Copyright information

© 2019 International Society of Gynecological Endocrinology

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gemzell-Danielsson, K., Meurice, M.E. (2019). Selective Progesterone Receptor Modulators for Contraception with Added Health Benefits. In: Berga, S., Genazzani, A., Naftolin, F., Petraglia, F. (eds) Menstrual Cycle Related Disorders. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-14358-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-14358-9_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-14357-2

  • Online ISBN: 978-3-030-14358-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation